Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs EOG Resources Inc (EOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs EOG Resources Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.27 (market cap $39.89B), while EOG Resources Inc trades at $135.72 (market cap $71.43B). The key difference: EOG Resources Inc is the larger of the two by market cap, and EOG Resources Inc pays a 3.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EOG | |
|---|---|---|
Market Cap | $39.89B | $71.43B |
Sector | Health | Energy |
52-Week High | $491.22 | $149.89 |
52-Week Low | $278.09 | $101.78 |
Enterprise Value | $38.15B | $75.88B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EOG Resources trades at $134.10, up 0.42% with a bullish technical outlook and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.41 exceeding expectations. Valuation metrics appear attractive with a P/E of 13.19 and EV/EBITDA of 6.36. Recent news highlights operational excellence and shareholder returns, including $8.5 billion in projected 2026 free cash flow. Technical indicators show support at $132 and resistance at $136.
Outlook remains positive driven by oil price strength and efficient operations, though risks include commodity volatility and capital expenditure pressures. Analyst consensus is strongly bullish with a $156.40 price target, representing 16.6% upside. The absence of sell ratings underscores confidence in EOG's financial health and strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
